Showing results (1-10 of 114) with videos related to
Sort By:
Pageof 12
Journal of Internal Medicine|June 15, 2021
Twenty-five years of biologicals in IBD: What´s all the hype about?Klaus R Herrlinger, Eduard F StangeExpert Review of Gastroenterology & Hepatology|July 22, 2023
Prioritization in inflammatory bowel disease therapyKlaus R Herrlinger, Eduard F StangeExpert Review of Gastroenterology & Hepatology|December 22, 2023
To STRIDE or not to STRIDE: a critique of "treat to target" in Crohn´s diseaseKlaus R Herrlinger, Eduard F StangeJournal of Crohn'S & Colitis|December 18, 2013
The debated role for thiopurines in Crohn's diseaseKlaus R Herrlinger, Eduard F StangeExpert Review of Gastroenterology & Hepatology|August 28, 2024
To STRIDE or not to STRIDE: a critique of "treat to target" in ulcerative colitisKlaus R Herrlinger, Eduard F StangeExpert Opinion on Biological Therapy|January 24, 2014
Therapeutic peptides in inflammatory bowel diseaseKlaus R Herrlinger, Eduard F Stange, Klaus FellermannWorld Journal of Gastroenterology|August 29, 2006
Extraintestinal manifestations and complications in inflammatory bowel diseasesKatja S Rothfuss, Eduard F Stange, Klaus R HerrlingerEuropean Journal of Gastroenterology & Hepatology|July 4, 2003
Crohn's disease: a defensin deficiency syndrome?Klaus Fellermann, Jan Wehkamp, Klaus R Herrlinger, et al.Inflammatory Bowel Diseases|October 9, 2004
Fatal staphylococcal sepsis in Crohn's disease after infliximabKlaus R Herrlinger, Annette Borutta, Gabriel Meinhardt, et al.Nature Clinical Practice. Gastroenterology & Hepatology|November 3, 2005
Mechanisms of disease: defensins in gastrointestinal diseasesJan Wehkamp, Klaus Fellermann, Klaus R Herrlinger, et al.Pageof 12